Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2379-2384

  Grégoire, Nicolas ^a   Raherison, Sophie ^b   Grignon, Claire ^a   Comets, Emmanuelle ^c   Marliat, Manuella ^a   Ploy, Marie Cécile ^b   Couet, William ^a  

^a UNIVERSITÉ DE POITIERS   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; CARRIER PROTEIN; CIPROFLOXACIN; DRUG CARRIER; MEX PROTEIN; PHENYLARGININE BETA NAPHTHYLAMIDE; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE AMPLIFICATION; GENE OVEREXPRESSION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; CROSS INFECTION; DIPEPTIDES; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 77952597327     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01478-08     Document Type: Article

References (38)

1. Aires, J. R., T. Kohler, H. Nikaido, and P. Plesiat. 1999. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 43:2624-2628.
2. Akasaka, T., M. Tanaka, A. Yamaguchi, and K. Sato. 2001. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45: 2263-2268.
3. Anthony, T. U., and L. G. Rubin. 1999. Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports). Antimicrob. Agents Chemother. 43:2074-2076.
4. Balaban, N. Q., J. Merrin, R. Chait, L. Kowalik, and S. Leibler. 2004. Bacterial persistence as a phenotypic switch. Science 305:1622-1625.
5. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
6. Bulitta, J. B., N. S. Ly, J. C. Yang, A. Forrest, W. J. Jusko, and B. T. Tsuji. 2009. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:46-56.
7. Chung, P., P. J. McNamara, J. J. Campion, and M. E. Evans. 2006. Mechanism- based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2957-2965.
8. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
9. Gould, I. M., K. Milne, G. Harvey, and C. Jason. 1991. Ionic binding, adaptive resistance and post-antibiotic effect of netilmicin and ciprofloxacin. J. Antimicrob. Chemother. 27:741-748.
10. Hocquet, D., P. Berthelot, M. Roussel-Delvallez, R. Favre, K. Jeannot, O. Bajolet, N. Marty, F. Grattard, P. Mariani-Kurkdjian, E. Bingen, M. O. Husson, G. Couetdic, and P. Plesiat. 2007. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob. Agents Chemother. 51:3531-3536.
11. Hocquet, D., C. Vogne, F. El Garch, A. Vejux, N. Gotoh, A. Lee, O. Lomovskaya, and P. Plesiat. 2003. MexXY-OprM efflux pump is necessary for adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 47:1371-1375.
12. Hooper, D. C. 1999. Mechanisms of fluoroquinolone resistance. Drug Resist. Updat. 2:38-55.
13. Jacoby, G. A. 2005. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 41:S120-S126.
14. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112:275-285.
15. Katsube, T., Y. Yamano, and Y. Yano. 2008. Pharmacokinetic- pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. J. Pharm. Sci. 97:1606-1614.
16. Kriengkauykiat, J., E. Porter, O. Lomovskaya, and A. Wong-Beringer. 2005. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:565-570.
17. Li, X. Z., H. Nikaido, and K. Poole. 1995. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1948-1953.
18. Macia, M. D., N. Borrell, M. Segura, C. Gomez, J. L. Perez, and A. Oliver. 2006. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:975-983.
19. Mager, D. E., E. Wyska, and W. J. Jusko. 2003. Diversity of mechanism-based pharmacodynamic models. Drug Metab. Dispos. 31:510-518.
20. Marquez, B. 2005. Bacterial efflux systems and efflux pumps inhibitors. Biochimie 87:1137-1147 .
21. Mesaros, N., Y. Glupczynski, L. Avrain, N. E. Caceres, P. M. Tulkens, and F. Van Bambeke. 2007. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 59:378-386.
22. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607.
23. Mouton, J. W., and A. A. Vinks. 2005. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin. Pharmacokinet. 44:201-210.
24. Mouton, J. W., A. A. Vinks, and N. C. Punt. 1997. Pharmacokinetic- pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob. Agents Chemother. 41:733-738.
25. Nielsen, E. I., A. Viberg, E. Lowdin, O. Cars, M. O. Karlsson, and M. Sandstrom. 2007. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob. Agents Chemother. 51:128-136.
26. Nolting, A., T. D. Costa, R. Vistelle, K. H. Rand, and H. Derendorf. 1996. Determination of free extracellular concentrations of piperacillin by microdialysis. J. Pharm. Sci. 85:369-372.
27. Obritsch, M. D., D. N. Fish, R. MacLaren, and R. Jung. 2005. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25:1353-1364. (Pubitemid 41407633)
28. Pasquali, F., and G. Manfreda. 2007. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. Vet. Microbiol. 119:304-310.
29. Plasencia, V., N. Borrell, M. D. Macia, B. Moya, J. L. Perez, and A. Oliver. 2007. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. Antimicrob. Agents Chemother. 51:2574-2581.
30. Ruiz, J. 2003. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 51:1109-1117.
31. Schmidt, S., S. N. Sabarinath, A. Barbour, D. Abbanat, P. Manitpisitkul, S. Sha, and H. Derendorf. 2009. Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:5039-5045.
32. Schuck, E. L., A. Dalhoff, H. Stass, and H. Derendorf. 2005. Pharmacokinetic/ pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form. Infection 33(Suppl. 2):22-28.
33. Schweizer, H. P. 2003. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet. Mol. Res. 2:48-62.
34. Tam, V. H., A. N. Schilling, and M. Nikolaou. 2005. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J. Antimicrob. Chemother. 55:699-706.
35. Turnidge, J. 1999. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58(Suppl. 2):29-36.
36. Van Bambeke, F., J. M. Michot, and P. M. Tulkens. 2003. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J. Antimicrob. Chemother. 51:1067-1077.
37. Venisse, N., N. Gregoire, M. Marliat, and W. Couet. 2008. Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans. Antimicrob. Agents Chemother. 52: 937-943.
38. Zhanel, G. G., D. J. Hoban, K. Schurek, and J. A. Karlowsky. 2004. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 24:529-535.